ProCE Banner Activity

GRAALL-2014/B Quest Cohort Analysis: Blinatumomab During Consolidation in Adults With High-Risk Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia

Slideset Download
Conference Coverage

In a nonrandomized cohort analysis of adult patients with high-risk BCP-ALL, those who received blinatumomab during consolidation had improved clinical outcomes, including a higher MRD rate, lower incidence of relapse, and longer disease-free survival.

Released: December 17, 2022

Expiration: December 16, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen